

The EU Framework Programme for Research and Innovation HORIZON 2020

EU research policy – contribution to pain research

Dr Anna Graca

Unit E4 Non-communicable diseases and the challenge of healthy ageing Health Directorate, DG Research and Innovation European Commission

Research and Innovation

EU Health Research: Aims



- Translate science to benefit citizens
- Test and demonstrate new healthcare models, approaches and tools
 - Promote healthy and active ageing
 - Improve health outcomes, reduce inequalities
 - Support a competitive health sector
 - Provide evidence-base for effective health policies development





EU Health Research: Tools



Collaborative research

Real-life solutions based on joint problem-solving

Public-private partnerships

Investing together for next generation medicines and treatments

Global co-operation

One world, one team working to solve common health challenges

Public partnerships

Harnessing global expertise to fight poverty-related diseases

Patients at the heart of R&I



In policy design

- Work programmes based on wide consultations:
 - Advisory Group: representative of European Patient Associations
 - workshops: participation patients
- Horizon 2020 topics are patient-centred
- Many events are triggered by patient organisations

In projects

Partners

- Patient recruitment
- Through ethics board, safety monitoring board, and patient input platform
- Offer patients' perspective on recruitment, study design, project communication
- Translate results in lay language, modify guidelines to better fit patients' needs, contribute to dissemination activities...



Pain research challenges



- > 20% of adults are estimated to suffer from pain globally
- Low back pain number-one cause of years lost to disability worldwide*
- Migraine affects 15% of all European citizens
- Affects all populations, unevenly distributed
- Complex aetiology: multidisciplinary approaches needed
- Comorbidity with chronic non-communicable diseases

2010 Global Burden of Disease Study







How pain is generated and can this process be prevented, halted, modulated, blocked, reversed?

How chronification of pain begins and progresses?

Research on pain is needed to decipher **underlying mechanisms**, develop effective therapies, meaningful diagnostics and comprehensive management approaches

- Identify biomarkers, brain circuitries, and other neurobiological mechanisms for the triggering and chronification of pain
- Establish faster & reliable diagnostic tool
- Determine high risk patients
- Identify potential drug targets
- Predict treatment response enabling improved stratified care





EU pain research – what's being funded FP7 & HORIZON 2020



Translational research

- acute pain
- chronic pain
- biomarkers
- imaging
- > models
- technology
- prevention
- early detection
- Clinical trials

€ 163 million (2007-2017/December)

FP7 projects



EUROHEADPAIN - Mechanisms and Treatment of Migraine and its Chronification

- ncRNAPain Non-coding RNAs in neurogenic and neuropathic pain mechanisms and their application for risk assessment, patient stratification and personalised pain medicine
- COMOESTAS COntinuous MOnitoring of Medication Overuse Headache in Europe and Latin America: development and STAndardization of an Alert and decision support System

UNDERNEATH MIGRAINE - Underneath the attack: cortical network function in migraine





NGN-PET - Modelling Neuron-Glia Networks into a drug discovery platform for Pain Efficacious Treatments

- PAINSTRAT Novel neurophysiological techniques to quantify pain and stratify patients
- RELIEF Recovering Life Wellbeing Through Pain Self-management Techniques Involving Icts
- > **PainCells** Decomposition of pain into cell types
- PainDynamics Research on the dynamics of attention bias for pain in daily life.



Risk factors and determinants for neuropathic pain

European Commission

Research and Innovation

DOLORisk (H2020 project)

- Comprehensive approach covering basic research on molecular, patient and population level
- Providing a platform to improve diagnosis & patients stratification according to risk profile
- Employing preventive strategies
- Developing novel therapeutics







http://dolorisk.eu

Underpinning EU Drug Strategy (2012-2020)

ATOME (FP7 project) – Commission access to opioid medications in Europe

- Substantial increase of controlled medicines consumption in developed countries
- EU Drug Strategy (2012-2020) aimed at controlling access to illicit drugs while ensuring access to prescribed controlled medicines (e.g. opioids)
- Evidence base for EU Drug Strategy (2012-2020) aimed at controlling access to illicit drugs while ensuring access to prescribed controlled medicines (e.g. opioids)
- ATOME analysing factors responsible for inappropriate use of/access to opioids and developing policy recommendations to Health Authorities
- WHO guidelines 'Ensuring Balance in National policies on controlled substances" based on ATOME results
 Research and



Accelerating the delivery of therapies





Developing the next generation of vaccines, medicines and treatments



The world's largest public private partnership in health research IMI – € 2 billion IMI 2 - € 3.3 billion

- Low Back Pain in IMI2's Strategic Research Agenda (2014-2020)
- ► EUROPAIN: increase understanding of chronic pain mechanisms; overall contribution € 22.5 million
- ► IMI2 7 call Pathological neuron-glia interactions in neuropathic pain (€1,5M)

Research and

Our current policy activities

Policy activities:

 Midterm review of the Digital Single Market (Communication includes digital transformation of health & care)

European Commission

- Personalised Medicine (Staff working document)
- Health Technology Assessment in Europe
- European Open Science Cloud

A trusted, open environment for sharing scientific data Linking data Connecting scientists globally Long term and sustainable

EC work programme 2018-2020

